椎间盘内注射亚甲蓝治疗椎间盘源性腰痛：一项随机对照试验的荟萃分析。

Intradiskal Injection of Methylene Blue for Discogenic Back Pain: A Meta-Analysis of Randomized Controlled Trials.

机构信息

Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, P. R. China.

Department of Orthopedics, Hainan Provincial People's Hospital, Haikou, Hainan, P. R. China.

出版信息

J Neurol Surg A Cent Eur Neurosurg. 2021 Mar;82(2):161-165. doi: 10.1055/s-0040-1721015. Epub 2021 Jan 21.

DOI:10.1055/s-0040-1721015

PMID:33477188

Abstract

INTRODUCTION

Intradiskal injection of methylene blue has some potential in alleviating discogenic back pain. This meta-analysis aims to explore the impact of intradiskal injection of methylene blue for discogenic back pain.

METHODS

Several databases such as PubMed, EMbase, Web of Science, EBSCO, and Cochrane Library databases have been searched through November 2019, and randomized controlled trials (RCTs) assessing the effect of intradiskal injection of methylene blue for discogenic back pain are included.

RESULTS

Three RCTs are included in the meta-analysis. Overall, compared with control group for discogenic back pain, intradiskal injection of methylene blue remarkably decreased pain scores at 3 months (mean difference [MD] = -0.71; 95% confidence interval [CI] = -0.96 to -0.46; < 0.00001) and 6 months (MD = -13.92; 95% CI = -22.31 to -5.54; = 001) and Oswestry Disability Index (ODI) at 4 to 6 weeks (MD = -10.39; 95% CI = -16.95 to -3.83; = 0.002) and 3 months (MD = -3.66; 95% CI = -4.85 to -2.48; < 0.00001), but demonstrated no obvious effect on ODI at 6 months (MD = -11.76; 95% CI = -33.33 to 9.80; = 0.28).

CONCLUSIONS

Intradiskal injection of methylene blue can substantially decrease pain scores and improve function for discogenic back pain.

摘要

简介

椎间盘内注射亚甲蓝在缓解椎间盘源性腰痛方面具有一定的潜力。本荟萃分析旨在探讨椎间盘内注射亚甲蓝治疗椎间盘源性腰痛的效果。

方法

检索了 PubMed、EMbase、Web of Science、EBSCO 和 Cochrane Library 等数据库，截至 2019 年 11 月，纳入评估椎间盘内注射亚甲蓝治疗椎间盘源性腰痛的随机对照试验（RCT）。

结果

本荟萃分析纳入了 3 项 RCT。总体而言，与椎间盘源性腰痛的对照组相比，椎间盘内注射亚甲蓝可显著降低 3 个月时的疼痛评分（均数差 [MD] = -0.71；95%置信区间 [CI] = -0.96 至 -0.46； < 0.00001）和 6 个月时的疼痛评分（MD = -13.92；95% CI = -22.31 至 -5.54； = 0.01）和 Oswestry 残疾指数（ODI）在 4 至 6 周时（MD = -10.39；95% CI = -16.95 至 -3.83； = 0.002）和 3 个月时（MD = -3.66；95% CI = -4.85 至 -2.48； < 0.00001），但在 6 个月时对 ODI 没有明显影响（MD = -11.76；95% CI = -33.33 至 9.80； = 0.28）。